Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;79(3):374-383.
doi: 10.1016/j.eururo.2020.11.021. Epub 2020 Dec 5.

A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer

Neil K Jairath  1 , Alan Dal Pra  2 , Randy Vince Jr  3 , Robert T Dess  1 , William C Jackson  1 , Jeffrey J Tosoian  3 , Sean M McBride  4 , Shuang G Zhao  1 , Alejandro Berlin  5 , Brandon A Mahal  6 , Amar U Kishan  7 , Robert B Den  8 , Stephen J Freedland  9 , Simpa S Salami  3 , Samuel D Kaffenberger  3 , Alan Pollack  2 , Phuoc Tran  10 , Rohit Mehra  11 , Todd M Morgan  3 , Adam B Weiner  12 , Osama Mohamad  13 , Peter R Carroll  14 , Matthew R Cooperberg  14 , R Jeffrey Karnes  15 , Paul L Nguyen  16 , Jeff M Michalski  17 , Jonathan D Tward  18 , Felix Y Feng  13 , Edward M Schaeffer  12 , Daniel E Spratt  19
Affiliations

A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer

Neil K Jairath et al. Eur Urol. 2021 Mar.

Abstract

Context: Molecular biomarkers aim to address the established limitations of clinicopathologic factors to accurately risk stratify patients with prostate cancer (PCa). Questions remain as to whether sufficient evidence supports adoption of these biomarkers for clinical use.

Objective: To perform a systematic review of the available evidence supporting the clinical utility of the Decipher genomic classifier (GC).

Evidence acquisition: The review was performed as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines by searching PubMed and conference abstracts from January 2010 to June 2020. Evidence was then graded using the criteria of Simon et al (Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-52) and American Urology Association (AUA) criteria.

Evidence synthesis: In total, 42 studies and 30407 patients were included. GC performance data were available for localized, postprostatectomy, nonmetastatic castration-resistant, and metastatic hormone-sensitive PCa as part of retrospective studies (n=12141), prospective registries (n=17053), and prospective and post hoc randomized trial analyses (n=1213). In 32 studies (n=12600), the GC was independently prognostic for all study endpoints (adverse pathology, biochemical failure, metastasis, and cancer-specific and overall survival) on multivariable analysis and improved the discrimination over standard of care in 24 studies (n=8543). GC use changed the management in active surveillance (number needed to test [NNT]=9) and postprostatectomy (NNT=1.5-4) settings in five studies (n=4331). Evidence strength was levels 1 and 2 by the Simon criteria for all disease states other than high-risk PCa, and grades A and B by AUA criteria depending on disease state.

Conclusions: Consistent data are now present from diverse levels of evidence, which when viewed together, have demonstrated clinical utility of the GC in PCa. The utility of the GC is strongest for intermediate-risk PCa and postprostatectomy decision-making.

Patient summary: In this paper, we review the evidence of the Decipher genomic classification tool for men with prostate cancer. We found consistent evidence that the test helps identify which cancers are more or less aggressive, which in turn aids in personalized treatment decision-making.

Keywords: Biomarkers; Decipher; Prognosis; Prostate cancer.

PubMed Disclaimer

Publication types